Help us find a cure!
Learn how >
The US HAEA provides any clinical trial information provided to us by our pharmaceutical sponsors immediately upon receipt.
A bradykinin antagonist receptor (Firazyr) is being evaluated for the treatment of acute attacks in children with Hereditary Angioedema (HAE).
A patient registry is open to participants, to collect data on the safety of C1 inhibitor (Berinert) in clinical practice in the United States. The duration of individual patient participation will vary and is determined by the frequency of HAE attacks and patient’s need for treatment.
If you are interested in participating in this trial, please contact US HAEA’s John Williamson, (972) 984-0621. Please return to this page often to check for updates. And contact any of our Patient Services Representatives to learn about all of the new FDA-approved HAE therapies, as well as treatments still under development, that can revolutionize HAE patients’ lives.
You may also wish to browse www.clinicaltrials.gov